Metformin And Sitagliptin

Introduction Overview

Generic Name

metformin and sitagliptin

Brand Name

Janumet XR

Dosage Form

Extended-release tablet

Drug Class

Antidiabetic combinations

Pharmacokinetics

Absorption: Janumet XR contains metformin and sitagliptin in a fixed-dose combination with extended-release properties. After oral administration, sitagliptin is rapidly absorbed, achieving peak plasma concentrations within approximately 1 to 4 hours. Metformin in the extended-release formulation is absorbed more slowly from the gastrointestinal tract, with peak plasma concentrations occurring within 7 hours following administration. Food intake does not significantly affect sitagliptin absorption; however, metformin absorption can be slightly delayed but overall bioavailability remains complete when administered with meals, which is recommended to reduce gastrointestinal side effects. Distribution: Sitagliptin has a moderate volume of distribution (~198 L), indicating distribution into body tissues, with approximately 38% plasma protein binding. Metformin exhibits minimal plasma protein binding, enabling widespread distribution, particularly accumulating in the gastrointestinal tract, liver, kidney, and bladder. Both drugs cross cellular membranes through specific transporters; metformin is taken up by the organic cation transporters (OCTs) predominantly in the liver and kidney, while sitagliptin's distribution is facilitated by passive diffusion and renal tubular reabsorption. Metformin does not bind significantly to plasma proteins, which impacts its elimination and lack of displacement interactions. Metabolism: Sitagliptin is minimally metabolized, primarily via CYP3A4 and CYP2C8 pathways, but most of the drug is excreted unchanged by renal elimination. Metformin is not metabolized by the liver, which is a key factor in its safety profile, especially regarding drug interactions. The lack of hepatic metabolism reduces the potential for cytochrome P450-mediated interactions. Elimination: Sitagliptin is predominantly eliminated unchanged renally, with a half-life of approximately 12.4 hours, allowing once-daily dosing. Metformin is excreted unchanged in the urine through a combination of glomerular filtration and active tubular secretion, with an elimination half-life of approximately 6.2 hours. Impaired renal function significantly affects the elimination of both drugs, raising the risk of accumulation and adverse effects such as lactic acidosis for metformin. Therefore, renal function monitoring is essential during therapy. Clinical studies have demonstrated that steady-state plasma concentrations for both agents are reached within 2-3 days of dosing. These pharmacokinetic characteristics enable Janumet XR to be administered once daily, simplifying the treatment regimen for patients with type 2 diabetes.

Dosage Forms

Available Dosage Forms: Janumet XR is available as extended-release tablets containing fixed doses of metformin hydrochloride and sitagliptin phosphate monohydrate. Specific dosage strengths commonly available include combinations such as metformin 500 mg with sitagliptin 50 mg, metformin 750 mg with sitagliptin 50 mg, and metformin 1000 mg with sitagliptin 50 mg, depending on regulatory approvals and manufacturing specifications. The extended-release formulation ensures gradual release of metformin to optimize tolerability and efficacy. Dosages for Adults and Adolescents: Janumet XR is indicated for adult patients with type 2 diabetes mellitus to improve glycemic control, typically initiated at doses containing metformin 500 mg and sitagliptin 50 mg once daily with meals. Dosage adjustments may be made based on glycemic response and tolerability, with maximum daily doses usually not exceeding metformin 2000 mg and sitagliptin 100 mg total per day, divided dosing or combinations available as clinically warranted. The extended-release tablet should be swallowed whole and not crushed, chewed, or broken to preserve the release characteristics. Specific Patient Populations: Use in patients with renal impairment requires careful consideration; Janumet XR is contraindicated in patients with severe kidney disease (eGFR below recommended thresholds for metformin use). Dosage modifications or discontinuation may be necessary in elderly patients or those with hepatic impairment due to increased risks of lactic acidosis. Special populations such as pregnant or breastfeeding women require individualized assessment, with limited data on safety but general recommendations for glucose control applicable. Pediatric use has not been well established, and Janumet XR is generally not recommended for children or adolescents under 18 years old. Patients undergoing radiologic studies involving iodinated contrast media must temporarily discontinue therapy to prevent renal adverse effects. Proper storage conditions include maintaining room temperature away from moisture and heat, with some formulations requiring storage in original containers and use within specified periods after opening.

Mechanism Of Action

Janumet XR is a synergistic antidiabetic combination containing metformin and sitagliptin, targeting distinct pathways involved in glucose homeostasis to improve glycemic control in type 2 diabetes mellitus. Metformin primarily acts by decreasing hepatic glucose production through inhibition of mitochondrial respiratory chain complex I, resulting in decreased gluconeogenesis. This suppression lowers fasting plasma glucose and reduces insulin resistance in peripheral tissues, improving glucose uptake by skeletal muscle and adipose tissue. Additionally, metformin enhances insulin sensitivity and has beneficial effects on lipid metabolism, contributing to cardiovascular risk reduction. Sitagliptin is a potent and selective inhibitor of dipeptidyl peptidase-4 (DPP-4), an enzyme responsible for degrading incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). By inhibiting DPP-4, sitagliptin prolongs the biologic activity of endogenous incretins, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner. This mechanism reduces postprandial and fasting blood glucose levels without significant risk of hypoglycemia. The combination of metformin with sitagliptin in Janumet XR provides complementary effects: metformin reduces hepatic glucose output while sitagliptin enhances pancreatic beta-cell responsiveness and suppresses inappropriate glucagon secretion. This multi-targeted approach addresses the pathophysiological defects in type 2 diabetes more effectively than monotherapy. Clinical trials have demonstrated that this combination improves glycemic parameters such as HbA1c, fasting plasma glucose, and postprandial glucose levels to a greater extent than either agent alone. Furthermore, sitagliptin's glucose-dependent mechanism reduces the risk of hypoglycemia compared with traditional insulin secretagogues. Overall, Janumet XR offers a convenient once-daily dosing regimen that combines the pharmacodynamic benefits of both drugs, with improved patient adherence and tolerability due to its extended-release metformin formulation and the favorable safety profile of sitagliptin. Ongoing research continues to explore the long-term cardiovascular and renal outcomes associated with this combination therapy.

Pharmacological Actions

Reduces hepatic gluconeogenesis and glucose output via metformin's action.
Enhances peripheral insulin sensitivity promoting increased glucose uptake.
Inhibits dipeptidyl peptidase-4 enzyme, prolonging incretin hormone activity.
Stimulates glucose-dependent insulin secretion and suppresses glucagon release.
Lowers both fasting and postprandial blood glucose levels effectively.
Supports weight neutrality or modest weight loss through metformin component.
Exerts no significant effect on beta-cell mass but improves function.
Minimizes hypoglycemia risk due to glucose-dependent incretin effects.
Improves glycemic control as part of combination therapy in type 2 diabetes.
May favorably influence lipid profiles and cardiovascular risk factors.
Does not cause significant hepatic metabolism or cytochrome P450 interactions.
Extended-release formulation improves gastrointestinal tolerability.
Reduces chronic hyperglycemia-associated complications by sustained control.
Has been associated with beneficial effects on beta-cell responsiveness.
Demonstrates additive efficacy compared to monotherapy with either agent.

Therapeutic Or Clinical Uses

Management of type 2 diabetes mellitus to improve glycemic control.
Useful in combination with diet and exercise for blood sugar control.
Adjunct therapy when monotherapy with metformin or DPP-4 inhibitor is insufficient.
Treatment option for patients inadequately controlled on sitagliptin or metformin alone.
Reduces fasting plasma glucose and postprandial glucose concentrations.
Helps reduce HbA1c levels to target values recommended by diabetes guidelines.
Alternative oral combination therapy to avoid insulin initiation in some cases.
Appropriate for patients who require dual mechanism action without hypoglycemia risk.
May delay progression of type 2 diabetes by improving beta-cell function.
Supports weight neutral management in overweight or obese diabetic patients.
May be employed as part of a comprehensive diabetes management plan including lifestyle modification.
Can be used when other antidiabetic agents are contraindicated or not tolerated.
Option for patients with renal impairment within dosing guidelines for metformin.
Supports long-term glycemic control with convenient once-daily dosing.
Potential use in preventing or delaying diabetes-related microvascular complications.

Side Or Adverse Effects

Hypoglycemia, particularly when combined with insulin or other antidiabetics.
Gastrointestinal disturbances including nausea, vomiting, diarrhea, and indigestion.
Headache and general weakness or fatigue.
Cold-like symptoms such as runny or stuffy nose, sneezing, and sore throat.
Signs of lactic acidosis, a rare but potentially fatal medical emergency.
Pancreatitis presenting as severe upper abdominal pain radiating to the back.
Severe skin reactions including itching, blistering, and peeling.
Joint pain or ongoing severe pain in joints.
Kidney dysfunction symptoms such as swelling, reduced urination, fatigue, or breathlessness.
Possible vitamin B12 deficiency with long-term metformin use.
Rare allergic reactions including hives, facial swelling, or breathing difficulty.
Weight neutral or modest weight loss, generally not inducing weight gain.
Possible dizziness, particularly at treatment initiation or dose changes.
Urticaria or other hypersensitivity manifestations in a small number of patients.
Rare reports of increased liver enzyme levels or liver dysfunction.

Precautions

Contraindicated in severe renal impairment due to risk of metformin accumulation.
Use cautiously in patients with a history of pancreatitis.
Monitor for signs of lactic acidosis especially in dehydration, infection, or hypoxia.
Assess vitamin B12 levels during prolonged therapy to prevent deficiency.
Temporary discontinuation advised prior to iodinated contrast imaging procedures.
Cautious use in elderly patients due to diminished renal function and comorbidities.
Monitor blood glucose regularly to avoid hypoglycemia when combined with insulin or secretagogues.
Avoid excessive alcohol consumption to reduce lactic acidosis risk and glycemic variability.
Patients should be advised not to crush or chew tablets to maintain extended-release property.
Inform providers about all concomitant medications to assess drug interaction risks.
Pregnant or breastfeeding patients should consult healthcare providers prior to use.
Ensure patient adherence to lifestyle modifications including diet and exercise.
Educate patients on hypoglycemia recognition and management.
Avoid use in patients with known hypersensitivity to metformin, sitagliptin, or excipients.
Regular monitoring of renal and hepatic function recommended during treatment.

Warnings

Do not use in severe kidney disease or metabolic acidosis including diabetic ketoacidosis.
High risk of lactic acidosis with metformin especially in renal impairment or hypoxic states.
Stop Janumet XR immediately and seek emergency care if symptoms of lactic acidosis occur.
May cause severe hypoglycemia when taken with insulin or other antidiabetic agents.
Observe for signs of pancreatitis and discontinue if suspected.
Severe skin reactions may require prompt discontinuation and medical evaluation.
Risk of kidney problems manifesting as swelling, decreased urination, or rapid weight gain.
May precipitate heart failure symptoms in susceptible patients; monitor appropriately.
Avoid use in patients with unstable or severe heart failure due to lactic acidosis risk.
Temporary discontinuation recommended before diagnostic studies involving intravascular iodinated contrast.
Potential stimulation of ovulation in premenopausal women increasing risk of unintended pregnancy.
Not recommended for patients with hypersensitivity to any component of Janumet XR.
Patients should be informed about the importance of adherence and reporting adverse effects.
Use with caution in conditions causing dehydration, sepsis, or hypoxemia.
Long-term safety beyond current indications has not been fully established.

Contraindication

Severe renal impairment or chronic kidney disease at eGFR below recommended thresholds.
Known hypersensitivity or allergy to metformin, sitagliptin, or any formulation components.
Metabolic acidosis of any etiology including diabetic ketoacidosis with or without coma.
Acute or chronic conditions that may deteriorate renal function such as dehydration or sepsis.
Patients undergoing radiologic studies with iodinated contrast unless treatment is temporarily stopped.
Severe hepatic impairment due to increased lactic acidosis risk.
Patients with acute pancreatitis or history of recurrent pancreatitis unless benefits outweigh risks.
Severe heart failure or unstable congestive heart failure states.
Age below 18 years, as safety and efficacy have not been established in pediatric populations.
Patients with severe gastrointestinal diseases that may affect drug absorption.
Known alcoholism or excessive alcohol intake adversely impacting therapy.
Pregnancy and lactation situations where risk-benefit assessment discourages use.
Conditions predisposing to hypoxia or hypoxemia including respiratory failure.
Unstable medical conditions with potential for rapid deterioration of renal function.
Situations compromising tissue perfusion or oxygen delivery.

Drug Interactions

Risk of hypoglycemia is increased when combined with insulin or insulin secretagogues (e.g., sulfonylureas).
Concurrent use with drugs that impair renal function may increase metformin accumulation and lactic acidosis risk.
Medications affecting gastrointestinal motility or absorption can alter metformin pharmacokinetics.
Cationic drugs eliminated by renal tubular secretion may compete with metformin elimination (e.g., cimetidine).
Use with iodinated contrast media increases risk of acute renal failure and lactic acidosis; temporary discontinuation recommended.
Drugs that increase blood glucose levels (e.g., corticosteroids, diuretics) may reduce efficacy of Janumet XR.
Sitagliptin metabolism minimally affected; however, caution with strong CYP3A4 inhibitors or inducers is advised.
Alcohol may potentiate metformin’s effect on lactate metabolism, increasing lactic acidosis risk.
Concomitant use of digoxin may require monitoring as sitagliptin can increase digoxin concentrations.
Other antidiabetic agents may have additive effects, necessitating dose adjustments to avoid hypoglycemia.
Drugs interfering with renal transporters (e.g., probenecid) could affect metformin elimination.
Beta-blockers and other sympatholytic agents may mask hypoglycemia symptoms.
Herbal supplements impacting blood glucose or renal function may interact and require monitoring.
Some medications may decrease sitagliptin levels through induction of hepatic enzymes though clinically insignificant generally.
Concomitant use of nephrotoxic agents requires caution and monitoring of renal function.

Preparations Of The Drug

Janumet XR extended-release tablets combining various strengths of metformin hydrochloride and sitagliptin phosphate monohydrate.
Combinations typically include metformin 500 mg, 750 mg, or 1000 mg with sitagliptin 50 mg per tablet.
Tablets are for oral administration, once daily dosing with meals to improve tolerability and adherence.
Formulations designed for gradual metformin release to minimize gastrointestinal adverse effects.
Available in blister packs or bottles depending on manufacturer and region.
Packaging instructions emphasize storage at room temperature away from moisture and excessive heat.
Guidance provided to avoid crushing or chewing tablets to maintain extended-release characteristics.
Patient leaflets include information on potential side effects, dosing instructions, and safe administration.
Some generic versions available with bioequivalence to the brand formulation.
Supplied as prescription-only medication with specific prescribing information.
Storage and shelf-life information tailored to maintain drug stability and efficacy.
Accompanying components such as packaging for easy identification and compliance.
Patient support materials often include glucose monitoring reminders and hypoglycemia management guidance.
Educational materials provided for healthcare practitioners regarding dose adjustment and contraindications.
Preformulated fixed-dose combination tablets improve patient convenience compared to individual agents.